Microbiome Diversity
Guidelines for e-signature use in global trials
Guidelines for e-signature use in global trials, including qualified e-signature and standard e-signature options.
By emily johnson · Sep 8, 2026
Guidelines for e-signature use in global trials, including qualified e-signature and standard e-signature options.
Ivonescimab surpasses Keytruda in overall survival for NSCLC first-line treatment, demonstrating potential breakthrough in lung cancer therapy.
Sensorion's HearConnex trial gets green light for hearing loss treatment with gene therapy SENS-601.
Alumis advances its lupus drug to Phase III trials despite mixed Phase IIb results, targeting a specific patient subgroup for better outcomes.
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.
© 2026 Vimeo Health. All rights reserved.
Theme by Auto UI Theme Builder.